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Abstract
Background: Postoperative upper gastrointestinal fistula (PUGIF) is a devastating complication, leading to high
mortality (reaching up to 80%), increased length of hospital stay, reduced health-related quality of life and increased
health costs. Nutritional support is a key component of therapy in such cases, which is related to the high prevalence
of malnutrition. In the prophylactic setting, enteral nutrition (EN) is associated with a shorter hospital stay, a lower
incidence of severe infectious complications, lower severity of complications and decreased cost compared to total
parenteral nutrition (TPN) following major upper gastrointestinal (GI) surgery. There is little evidence available for the
curative setting after fistula occurrence. We hypothesize that EN increases the 30-day fistula closure rate in PUGIF,
allowing better health-related quality of life without increasing the morbidity or mortality.
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Methods/design: The NUTRILEAK trial is a multicenter, randomized, parallel-group, open-label phase III trial to assess
the efficacy of EN (the experimental group) compared with TPN (the control group) in patients with PUGIF. The
primary objective of the study is to compare EN versus TPN in the treatment of PUGIF (after esophagogastric resection
including bariatric surgery, duodenojejunal resection or pancreatic resection with digestive tract violation) in terms of
the 30-day fistula closure rate. Secondary objectives are to evaluate the 6-month postrandomization fistula closure rate,
time of first fistula closure (in days), the medical- and surgical treatment-related complication rate at 6 months after
randomization, the fistula-related complication rate at 6 months after randomization, the type and severity of early (30
days after randomization) and late fistula-related complications (over 30 days after randomization), 30-day and 6-month
postrandomization mortality rate, nutritional status at day 30, day 60, day 90 and day 180 postrandomization, the mean
length of hospital stay, the patient’s health-related quality of life (by self-assessment questionnaire), oral feeding time
and direct costs of treatment. A total of 321 patients will be enrolled.
Discussion: The two nutritional supports are already used in daily practice, but most surgeons are reluctant to use the
enteral route in case of PUGIF. This study will be the first randomized trial testing the role of EN versus TPN in PUGIF.
Trial registration: ClinicalTrials.gov: NCT03742752. Registered on 14 November 2018.
Keywords: Enteral nutrition, Parenteral nutrition, Conservative treatment, Upper gastrointestinal fistula, Randomized
controlled trial
Background
The incidence of clinically significant postoperative
upper gastrointestinal fistula (PUGIF) surgery is approxi-
mately 4%–20%, and the associated mortality can be as
high as 80% [1]. Various clinical presentations are de-
scribed that can endanger the patient’s life. It is import-
ant to start explorations without delay when the
diagnosis of PUGIF is made as delayed management
could lead to a devastating prognosis. Optimal commu-
nication between the teams is mandatory for successful
treatment. When the clinical presentation is an im-
portant and acute sepsis the treatment should be sur-
gical, but when the clinical presentation is less
symptomatic or late the treatment should be more
conservative with a watch-and-wait or endoscopic
management [2, 3]. The diagnosis should be made
with the help of computed tomography (CT) scans
with oral contrast and low-insufflation early endos-
copy. The principles of treatment include transfer to
the intensive care unit, optimal perfusion, intensive
physiotherapy, antifungal and antibiotic treatment,
and eventually drainage and collection or fistula clos-
ure (when possible) in the absence of ischemia [2].
Some promising endoscopic techniques in the treat-
ment of PUGIF have been reported (such as over-the-
scope (OVESCO)-clip®), mainly in bariatric surgery and
often in case reports [4]. The results give information on
feasibility but are too weak to give information on effi-
ciency. Large defects cannot be treated with hemostatic
clips [2, 4, 5]. The fistula output can be reduced by som-
atostatin analogs [3, 6].
Several prognostic factors of PUGIF have been identi-
fied [7], such as high output, high concentration of toxic
bile acids and active digestive enzymes, a fistula tract
longer than 2 cm, elevated postoperative blood glycemia
[8] and malnutrition with serum albumin <30 g/l [3].
Nutritional support is a key component of PUGIF
management, related to the high prevalence of malnutri-
tion and nil-per-mouth requirements for fistula treat-
ment [9, 10]. Therefore, despite fasting, nutritional
support is mandatory, and both enteral nutrition (EN)
downstream of the site of leakage (via a feeding jejunost-
omy or a nasojejunal feeding tube placed radiologically
or endoscopically) [11] and parenteral nutrition are pos-
sible and currently used. However, the role of EN in
maintaining the small intestinal structure and function
and in improving postoperative outcomes is well estab-
lished. Enteral nutrients maintain the structural function
that are compromised by fasting and parenteral nutrition
[12, 13].
In the prophylactic setting (i.e., in a population with-
out fistula but at the risk of developing one) a published
systematic literature review [1] based on seven random-
ized trials showed that EN is associated with shorter
hospital stay, lower incidence of severe infectious com-
plications [14], lower severity of complications and de-
creased costs compared to total parenteral nutrition
(TPN) following major upper gastrointestinal (GI) sur-
gery [1, 15].
In the curative setting (after fistula occurrence) there
is evidence available. Only one randomized clinical trial
has suggested the superiority of EN over TPN after pan-
creatic surgery, with an increase in the 30-day fistula
closure rate from 37% in the TPN group to 60% in the
EN group [16]. This trial only included pancreatic fistula
and did not include all PUGIFs that can also occur after
esophagogastric resection, including bariatric surgery,
duodenojejunal resection or pancreatic resection with
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digestive tract violation, although the concept of enteral
nutritional support is highly relevant in all these situa-
tions. Even if EN seems to be promising, the potential
risk of increasing the leakage output related to a reflux
of nutritional liquid and/or to activate digestive enzymes,
consequently reducing the probability of fistula closure
rate or increasing the delay of fistula closure, may ex-
plain why surgeons are usually reluctant to provide EN
[4]. A few, small randomized studies suggested the feasi-
bility of EN in 47 patients with upper GI fistula [17] for
the treatment of esophagojejunal fistula after total gas-
trectomy in gastric cancer patients [18] and after PUGIF
following sleeve gastrectomy [19, 20], but to date no ran-
domized study has been designed to test the superiority
of EN versus TPN in PUGIF.
Our study aim is thus to demonstrate the superiority




The NUTRILEAK trial is a multicenter, randomized,
parallel-group, open-label, phase III study to assess the
efficacy of EN compared to TPN in patients with PUGIF.
After informed consent, patients will be randomized in a
2:1 ratio to the EN treatment arm and the TPN com-
parator arm. Patients will be randomized to receive EN
through jejunostomy or nasojejunal tube, or to receive
TPN through central venous access, a peripherally
inserted central catheter line, totally implantable venous
access or any other approved TPN device.
Any other surgical or endoscopic procedures aiming at
directly closing the defect will not be allowed (including
surgical closure and endoscopic clip, prosthesis or glue)
throughout the whole study period. These measures
have not been scientifically demonstrated to be efficient
in this situation at this time and could be a confounding
factor regarding our primary objective.
By contrast, surgical, radiological or endoscopic fistula
drainage will be allowed throughout the whole study
period. Any interruption of more than 24 h in the treat-
ment determined by randomization (EN or TPN) will be
reported, with the cause, duration and solutions given
(i.e., the treatment provided or a switch to TPN in the
EN group). During hospitalization, patients will be evalu-
ated daily until fistula closure, with any fistula- or proto-
col treatment-related complication viewed through
physical examination and, if required, through routine
laboratory tests and/or imaging according to the usual
practice of each center.
The present study protocol was written in compliance
with the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 [21]. A completed
SPIRIT checklist is available as Additional file 1, and the
schedule of this study is presented in Fig. 1.
The study flowchart is shown in Fig. 2.
Objectives
The primary objective is to demonstrate the superiority
of EN over TPN in the treatment of PUGIF after eso-
phagogastric resection including bariatric surgery, duo-
denojejunal resection or pancreatic resection with
digestive tract violation in terms of the 30-day fistula
closure rate.
Secondary objectives are the assessment of: 1) 6-
month postrandomization fistula closure rate; 2) time of
first fistula closure (in days); 3) medical and surgical
treatment-related complication rate (EN or TPN) at 6
months after randomization; 4) fistula-related complica-
tion rate at 6 months after randomization; 5) type and
severity of early (30 days after randomization) and late
(over 30 days after randomization) fistula-related compli-
cations; 6) 30-day and 6-month postrandomization mor-
tality; 7) nutritional status at day 30, day 60, day 90 and
day 180 postrandomization; 8) mean length of hospital
stay; 9) patient health-related quality of life (by self-
assessment questionnaire); 10) time for oral feeding; and
11) direct costs of treatment.
Inclusion criteria
All patients diagnosed with a postoperative digestive fis-
tula in the recruiting centers will be screened for eligibil-
ity to participate in the study. Inclusion criteria are
patients who: 1) are older than 18 years of age; 2) signed
the written informed consent form (Additional file 2); 3)
underwent upper GI surgery for benign or malignant
disease (i.e., esophagogastric resection including bariatric
surgery, duodenojejunal resection or pancreatic resection
with digestive tract violation); 4) have had the diagnosis
of an active postoperative digestive fistula untreated or
persisting after failure of a dedicated surgical or endo-
scopic procedure to close the fistula (the fistula should
have been diagnosed less than 72 h before randomization
and confirmed by at least two criteria among the follow-
ing: clinical symptoms, CT scan/ultrasonic imaging/
endoscopic diagnosis, biologic/bacteriology diagnosis on
fluid output, intraoperative diagnosis at time of reopera-
tion); 5) have the indication of nil-per-mouth or just
clear liquids for comfort; 6) require an artificial nutri-
tional support; 7) have an American Society of Anes-
thesiologists (ASA) score of 1, 2 or 3; 8) have a life
expectancy longer than 6 months; 9) have no history
of allergy or product intolerance to the nutritional
product used in the study; 10) have ongoing health-
care insurance; and 11) are able to understand the in-
formation letter.
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Exclusion criteria
Patients with any of the following criteria will not be in-
cluded in the study: 1) scheduled surgical or endoscopic
treatment with the aim of closing the fistula (suture,
prosthesis, clip or glue); in case of treatment failure, pa-
tients are eligible to participate to the study; endoscopic
or surgical drainage are not exclusion criteria (meaning
that drainage is authorized only before randomization);
2) patient diagnosed with an isolated pancreatic fistula
(without digestive content) after a pancreatic resection
without digestive tract violation; 3) history of current se-
vere uncontrolled cardiovascular, pulmonary, renal or
liver failure; 4) presence of a severe and evolutive life-
threatening pathology; 5) uncontrolled sepsis/situation
related to the fistula (including, but not limited to, ab-
scess, bleeding, fistula with the trachea or the aorta); 6)
requirement of a nutritional support combining both the
enteral and parenteral routes together; 7) peritoneal car-
cinomatosis or distant metastasis; 8) pregnant and/or
lactating women; 9) freedom privacy; and 10) patient
Fig. 1 Schedule of the trial interventions and assessments. *Enteral nutrition (EN) or total parenteral nutrition (TPN) will be continued until the
oral intake reaches at least 60% of daily requirements. **Computed tomography (CT) scan with contrast injection for patient who do not show
any output of fluid during 48 h in wound or drainage. EQ5D EuroQol five dimensions, SF-36 36-item Short Form
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currently participating or having participated in another
interventional clinical trial related to nutritional support
or fistula management during 30 days prior to the begin-
ning of the study (note that participation in a prior clinical
trial not related to nutritional support or fistula manage-
ment does not exclude the patient from participation).
End points
The primary end point is the fistula closure rate at 30
days after randomization. Fistula closure will be defined
as no output fluid for 48 h in the wound or drainage and
absence of any fluid collection on imaging (CT scan with
contrast injection). The secondary end points are: 1) 6-
month fistula closure rate; 2) time of first fistula closure,
defined as time in days from randomization to first fis-
tula closure within 6 months after randomization; 3)
medical and surgical treatment-related complication rate
at 6 months, including complications related to the nu-
tritional support such as tube -related complications
(dislodgment, infection, occlusion), venous catheter -re-
lated complications (thrombosis, infection), or any other
nutritional route-related complications; 4) fistula-related
complication rate at 6 months; 5) type and severity of
early (before 30 days after randomization) and late (over
30 days after randomization) complications according to
the Dindo–Clavien classification [22]; 6) mortality within
30 days and within 6months after randomization; 7) nu-
tritional status will be evaluated at day 30, day 60, day
90 and day 180 postrandomization based on weight,
serum albumin and prealbumin concentration, C-
reactive protein and grip test (muscular strength); 8)
length of hospital stay in a health care structure (includ-
ing home hospitalization) based on the cumulative num-
ber of days of hospitalization during the whole study
period (from randomization until the end of the study);
9) patient health-related quality of life score based on
the 36-item Short Form and EuroQoL five-dimensions
questionnaires at inclusion and at days 30, 60, 90 and
180; 10) time from randomization to the oral diet cover-
ing at least 60% of the patient’s daily requirement ; 11)
direct economic costs of therapy from a societal perspec-
tive, including the costs of hospitalization (inpatient and
home settings), nutritional products, and early and late
complications occurring during follow-up.
Randomization
Patients will be randomized at inclusion during
hospitalization after verification of their suitability for in-
clusion. Patients will be randomized using the Clinsight
system (ENNOV). Randomizing two cases for one control
has been chosen based on the positive results of the study
by Klek et al. exhibiting a higher 30-day fistula closure rate
in the EN group for patients with pancreatic fistula, which
has a similar context [16]. In addition, European guide-
lines are in favor of EN for patients needing artificial nu-
trition with a grade A level of evidence (without the
context of PUGIF where nothing has been demonstrated
to date). A dynamic randomization procedure by
minimization will be performed to achieve a balance be-
tween the following prognostic factors: the type of fistula
(high- versus low-output, where a high-output fistula is
defined as effluent greater than 200ml/24 h), malignant/
Fig. 2 Flowchart of the trial. D day, EN enteral nutrition, GI gastrointestinal, TPN total parenteral nutrition, V visit
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nonmalignant disease, and somatostatin analog use. The
variable of treatment center will also be considered in the
minimization procedure. Taking into account the fistula
outflow, stratification on the surgical procedure/organ will
not be included in the minimization procedure since the
two are strongly linked.
Treatment methods
Each nutritional support will be planned to provide a
similar amount of calories and proteins. According to
the French guidelines on perioperative nutrition [23] the
amount of calories will be 30–35 kcal/kg/day including
proteins. The protein or amino acid intake will represent
18–20% of caloric intake: 1.35–1.5 g/kg/day (i.e., nitro-
gen at 0.21–0.24 g/kg/day).
EN or TPN will start in the first 72 h following
randomization with the need for tube or catheter place-
ment (if not already placed and according to
randomization arm) in the meantime.
EN can be delivered through a jejunostomy or a naso-
jejunal tube. A polymeric hypercaloric hyperprotidic
product without immunonutrients will be chosen. The
nutritional product will be the one usually used in each
center. EN will be started slowly (20 ml/h) with a pro-
gressive increase in the infusion rate every day according
to the tolerance of the patient. The expected infusion
rate to cover nutritional needs should be obtained in a
week. If the tolerance of EN does not allow the energy
and protein requirements to be met at the end of the
first week it will be necessary to start a complementary
parenteral nutrition to make up the nutritional require-
ments. EN will be infused at a continuous rate via an en-
teral pump. In the case of obstruction or failing of the
enteral tube, a feeding tube should be replaced immedi-
ately with the agreement of the surgeon. If it is impos-
sible to replace an enteral tube, parenteral nutrition
should be started on the same day.
TPN will be delivered through a central venous access,
a peripherally inserted central catheter line or a totally
implantable venous access port or any other approved
TPN device. The parenteral nutritional product will be
chosen according to the patient’s nutritional require-
ments as defined in the study and according to the usual
care of each center (industrial or compounding bag).
However, it is recommended to avoid a parenteral for-
mulation containing a long-chain triglyceride lipid emul-
sion and to add intravenous glutamine (Dipeptiven®) in
the TPN [24]. If Dipeptiven® is added to parenteral nu-
trition (recommended dose of 0.3–0.5 g/kg/day of dipep-
tide), the amount of amino acids (or nitrogen) will be
included in the calculated amount of protein intake. Par-
enteral nutrition will include electrolytes, vitamins and
trace elements every day. Serum levels of phosphate
should be assessed every 72 h. TPN should be infused
over 24 h with a pump. In case of catheter obstruction
or bacteremia related to the catheter, the central venous
catheter will be replaced and complications will be
treated according to guidelines [25, 26].
Patients will have appropriate care according to local
procedures to avoid complications with the feeding tube
or enteral venous catheter.
For all patients, glycemia will be checked regularly. In
case of hyperglycemia (>10mmol/l or >1.8 g/l), glycemia
should be maintained between 7.8 and 10mmol/l (1.4 to
1.8 g/l) with the use of insulin.
Nil-per-mouth (except a maximum of 500 ml/day of
clear liquids for comfort) will be required during fistula
treatment and until at least 5 days after fistula closure.
After this, oral alimentation will be progressively intro-
duced under the supervision of a nutritionist using a
previously known energetic value, and the proportion of
oral alimentation ingested will be monitored daily.
Data collection and follow-up
Follow-up of the patients will be at 30, 60, 90 and 180
days after randomization. The follow-up protocol in-
cludes a clinical examination (weight, temperature, arter-
ial blood pressure), assessment of the status of fistula
closure, paraclinic examination (CT scan with injection
and ingestion of contrast product) for patients who do
not show any output of fluid during 48 h in the wound or
drainage, assessment of time to first fistula closure
through the autoevaluation of fistula-associated symptoms
questionnaire, laboratory tests (blood cell count,
hemoglobin, white blood cell count with neutrophils, lym-
phocytes, monocytes, eosinophils, basophils, platelets,
hematocrit, red blood cell count, aspartate transaminase,
alanine aminotransaminase, alkaline phosphatase, γ-
glutamyltransferase, total bilirubin, creatinine, C-reactive
protein, serum albumin and prealbumin concentration,
total protein, sodium, potassium, chloride, urea, glucose),
nutritional assessment (weight, total protein, serum albu-
min and prealbumin concentration), a grip test for muscu-
lar strength measurement, assessment of the World
Health Organization Performance Status, and quality of
life questionnaires (36-item Short Form and EuroQoL
five-dimensions questionnaire).
The study is planned to last 42 months, with a 36-
month inclusion period and a 6-month follow-up period.
The results of the primary end point will be available 30
days after the end of the inclusion period (3 years).
Participating centers
To prevent institutional bias, the centers participating in
this trial are experienced in upper GI surgery. In this
study, 27 French centers will participate: Lille University
Hospital (two departments), Bordeaux University Hos-
pital (two departments), Lyon University Hospital (two
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centers), Amiens University Hospital, Brest University
Hospital, Caen University Hospital, Clermont-Ferrand
University Hospital, Diaconesses Hospital, Dijon Univer-
sity Hospital, Limoges University Hospital, North Uni-
versity Hospital of Marseille, Institut Mutualiste
Montsouris, Montpellier University Hospital, Saint-
Antoine University Hospital, Saint- Louis University
Hospital, Bichat University Hospital, Cochin University
Hospital, Institut Gustave Roussy, Reims University Hos-
pital, Rennes University Hospital, Rouen University Hos-
pital, Strasbourg University Hospital, Toulouse University
Hospital and Tours University Hospital.
Statistical evaluation and sample size
The hypothesis of this phase III study is that the use of
EN will improve the fistula closure rate at 30 days after
randomization. According to Klek et al. [16], the 30-day
fistula closure rate is expected to be 35% in the TPN
group and 55% in the EN group. According to Rutegård
et al. [27], we expect 10% mortality within 30 days. Con-
sidering a 35% fistula closure rate in the TPN group and
an expected 55% rate in the EN group (absolute differ-
ence of 20%, relative risk 1.57), a two-sided test, a type I
error of 0.05, a 90% power, an allocation rate of 2:1 for
the EN group and the TPN group, respectively, and tak-
ing into account 30-day mortality of 10%, 214 patients
are needed in the EN group and 107 in the TPN group,
leading to a total number of 321 patients to be recruited.
The intention-to-treat (ITT) population will comprise
all randomized patients, whether or not they satisfy the
eligibility criteria and irrespective of the study treatment
actually received. Unless otherwise indicated, all efficacy
and safety analyses (including the primary outcome) will
be conducted on the ITT population.
The per-protocol (PP) population will consist of all
ITT patients who complied with the protocol require-
ments. Compliance with protocol requirements will be
addressed through the review of protocol deviations/vio-
lations at the time of a blind data review meeting, just
prior to database lock. Any significant issues may war-
rant patient exclusion of all or part of their assessment
data. The PP population will be applied only for the pri-
mary outcome and will be considered as a secondary
analysis. For example, if an EN subject was intolerant for
48 h, and then switched to TPN for support, they will be
analyzed in the EN group in the ITT analysis and the
TPN group in the PP analyses.
No interim analysis is planned.
Statistical analyses will be independently performed by
the Biostatistics Department of the University of Lille
under the responsibility of AD. Data will be analyzed
using SAS software (SAS Institute Inc., Cary, NC, USA)
and all statistical tests will be performed with a two-
sided alpha risk of 0.05. A detailed statistical analysis
plan will be written and finalized prior to the database
lock. The data analysts will be blinded to the treatment
arm. Any deviation from the protocol-specified analysis
will be documented within a protocol amendment or
statistical analysis plan, as appropriate, and described
within the clinical study report.
Patient accountability will be summarized by treat-
ment group and overall for all randomized patients. In
addition, patient accountability information for screen-
failure patients will be collected and reported. The num-
ber of patients randomized will be summarized along
with the number of patients within each patient popula-
tion. In addition, the number of patients completing/not
completing the study will be presented along with the
primary reason for withdrawal from the study.
Deviations that warrant patient exclusion from the PP
population will be determined just prior to database lock
and documented within the relevant patient listing.
Some subgroup analyses, considered as exploratory,
will be performed according to some well-known factors
linked to the primary outcomes and considered in the
randomization per minimization technique: 1) type of
fistula (high- versus low-output fistula where high-
output fistula is defined as effluent greater than 200 ml/
24 h); 2) malignant/nonmalignant disease; and 3) som-
atostatin analog use or not.
Baseline characteristics will be described for each arm
for the ITT population. Quantitative variables will be
expressed as mean (standard deviation), median (inter-
quartile range) and range. Qualitative variables will be
expressed as frequencies and percentages. Normality of
distributions will be assessed graphically and using the
Shapiro–Wilk test.
Medico-economic analysis
Considering the clinical design, a full economic evalu-
ation will be performed taking into account both bene-
fits and costs. The analysis will be conducted in
concordance with Haute Autorité de Santé guidelines
[28]. Cost-effectiveness analysis will be performed ac-
cording to the ITT principle and from a societal per-
spective. A PP complementary analysis is planned as
many patients are expected to switch from TPN to EN.
The following costs will be considered in the economic
analysis: 1) hospitalization (inpatient and home settings);
2) nutritional products; and 3) management of early (be-
fore 30 days after randomization) and late (over 30 days
after randomization) complications occurring during
follow-up.
The costs of hospitalization (inpatient) will be com-
puted using the French hospital production costs study
(Echelle Nationale des Couts à la Methodologie Com-
mune Medecine Chirurgie Obstetrique). The average
cost will be adjusted to the length of stay (secondary end
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point) and the number of days in intensive care units,
which are known to be the main cost drivers. Home hos-
pitalizations will be valued by reference to the French
home hospitalization production costs study (Echelle
nationale des Couts-Hospitalisation à Domicile). All hos-
pitalizations will be recorded in the electronic case re-
port form (gathering data on the hospital to which the
patient was admitted, their main diagnosis, the date of
admission and the date of discharge) at each scheduled
clinical examination. Information on diagnosis-related
groups (Groupe Homogène de Malades; inpatient set-
ting) or management-related groups (Groupe Homogène
de Prise en Charge; home care setting) will be requested
at the end of the study by the study coordinator from
hospitals to which patients were admitted. Nutritional
products will be valued at their current price.
Quality-adjusted life years will be computed using the
French value set by a linear interpolation between dates
of measurement (inclusion and days 30, 60, 90 and 180)
[29]. Considering follow-up, costs and quality-adjusted
life years will not be discounted.
Ethical approval
This study protocol was approved on 2 November 2018
by the national ethics board and written informed con-
sent will be obtained from all participants in the trial by
the study investigators in each center. The results will be
presented at scientific meetings and published in
periodicals.
Confidentiality
Information about study subjects will be kept confiden-
tial. All data will be entered into a dedicated data man-
agement system and, as in all data document studies,
subjects will be assigned an individual identifying code
which does not contain any identifying information.
Discussion
Despite considerable improvements in surgical tech-
niques, PUGIF remains a worrying problem and there is
an urgent requirement for improving outcomes after
PUGIF normally associated with high mortality and
morbidity. Nutritional support is mandatory to acceler-
ate the healing of the fistula. However, the best route to
deliver nutrition is still subject to debate in the litera-
ture. EN and TPN are already used in daily practice, but
some surgeons are often reluctant to use EN in PUGIF.
Nutrients via the GI tract stimulate a complex re-
sponse that has implications on body composition and
immunologic integrity. The mechanisms include non-
specific luminal stimulation provided by nutrients,
“functional workload”, potential stimulation of pancrea-
ticobiliary secretions, secretion of humoral mediators,
and induction of intestinal hyperemia [12, 13].
EN has been shown to be efficient in the prophylactic
setting [1, 15], leading to a high probability of efficiency
in the curative setting when the fistula is in place. In a
well-designed randomized trial, EN was associated with
significantly higher closure rates and shorter closure
time for postoperative pancreatic fistula [16]. EN was
identified as an independent factor significantly associ-
ated with fistula closure (odds ratio 6.136, 95% confi-
dence interval 1.204–41.623; P = 0.043).
The transversal approach in this trial, with the inclu-
sion of various upper GI surgeries, will help to validate
the concept of the use of EN after fistula across different
surgical subspecialties. The trial results could modify na-
tional and international guidelines and practices world-
wide, offering a high level of evidence.
To conclude, in the NUTRILEAK study we aim to test
the hypothesis of the superiority of EN over TPN in
PUGIF in a large, multicentered, phase III, prospective
controlled, open-label trial. This trial will also assess pa-
tient quality of life and medico-economic effects of the
different treatment strategies.
Trial status
This is protocol version 2.0 (1 February 2019). The trial
is registered at ClinicalTrials.gov with the identifier
NCT03742752. This trial is currently ongoing. The re-
cruitment of subjects began in February 2019 is expected
to finish in February 2022.
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